Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.44 |
| ▸ | TACR2 | P21452 | 7/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770096 | 0.80 | SLC6A2 (0.56) | MCHR1TACR2CCR5 | |
| SCHEMBL4475059 | 0.73 | ALDH1A1 (0.38) | MCHR1 | |
| SCHEMBL6770900 | 0.71 | SLC6A4 (0.44) | — | |
| SCHEMBL6770174 | 0.70 | SLC6A4 (0.47) | — | |
| SCHEMBL758200 | 0.69 | TACR2 (0.70) | TACR2 | |
| SCHEMBL4468911 | 0.69 | SLC6A2 (0.38) | — | |
| SCHEMBL4471202 | 0.68 | ALDH1A1 (0.37) | — | |
| SCHEMBL6770103 | 0.67 | SLC6A2 (0.59) | MCHR1TACR2 | |
| SCHEMBL4483290 | 0.67 | SLC6A2 (0.45) | — | |
| SCHEMBL8590342 | 0.66 | MCHR1 (0.54) | MCHR1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | HRH2, PROKR2, BDKRB2 | MCHR1 237/4885TACR2 7/4885CCR5 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.